Leukapheresis yield in advanced sarcoma patients
| Sarcoma subtype | Age | Chemotherapy prior to leukapharesis | Sites of disease | Leukapharesis yield (×10^9) | Yield of CD25 depletion (×10^9) | |
|---|---|---|---|---|---|---|
| Patient 1 | SS | 47 | None | Soft tissue, lung, brain | 7.11 | 0.99 |
| Patient 2 | MRCL | 35 | Rtx | Bone, soft tissue, lung | 6.9 | 1.44 |
| Patient 3 | SS | 48 | A/I, HD Ifos, Rtx | Brain, lung | 5.14 | 1.2 |
| Patient 4 | SS | 46 | A/I/Vincristine, Rtx/Ifos | Lung | 14 | 1.365 |
| Patient 5 | SS | 26 | None | Lung, kidney, soft tissue | 11.2 | 1.56 |
| Patient 6 | SS | 42 | None | Recurrent, locally advanced axillary disease | 13.76 | 1.46 |
Rtx - Radiation therapy; A/I - Adriamycin and Ifosfamide; Gem/tax - gemcitabine and docetaxel; Doxil - liposomal doxorubicin; A/I/DTIC - Adriamycin, Ifosfamide and Decarbazine.